Pfizer beats Q4 profit estimates despite COVID-19 sales decline

Pfizer reported Q4 2025 revenue of $17.56 billion, above the Refinitiv consensus of $16.95 billion, and adjusted EPS of $0.66 beat estimates of $0.57 (reported loss per share $0.29). Sales of COVID-19 products plunged—Comirnaty down 35% and Paxlovid down 70% operationally—while ex-COVID operational revenues rose 9% (non-COVID portfolio +6%) with strong growth in Abrysvo (+136% op), oncology biosimilars (+76%), Eliquis (+8%), Prevnar (+8%) and Vyndaqel (+7%). Management reaffirmed 2026 guidance of $59.5–$62.5 billion revenue and adjusted diluted EPS $2.80–$3.00, factoring in roughly $5 billion of COVID sales, loss of exclusivity, drug-pricing pressures and tariffs, a mix that explains the stock's intraday pullback despite the beat.

Analysis

Winners from this print are Pfizer’s non-COVID franchises (Abrysvo, Prevnar, Eliquis, oncology biosimilars, Vyndaqel) which show double- to high-single-digit operational growth and are replacing ~$5B of COVID tail revenues; losers include pure-play COVID dependents (vaccine-only names, diagnostics and small-cap therapeutics tied to pandemic demand) as governments scale back purchases. Competitive dynamics tilt toward diversified incumbents: Pfizer’s breadth reduces single-product concentration risk and gives it pricing leverage in established vaccines/anticoagulants even as LOE and drug-pricing/tariff headwinds compress margins over 2-4 years.

Tail risks include a larger-than-guided drop in COVID sales (down >50% from the $5B assumption), adverse Medicare/pricing rulings, or major Phase III failures among the ~20 pivotal studies slated for 2026; these could cut guidance by >10% and widen credit spreads within weeks. Timing: expect immediate (days) volatility post-print, catalytic readouts and regulatory decisions over 6–18 months, and structural revenue shifts over 2–4 years as LOE and biosimilar competition materialize.

Trade implications: favor tactical equity exposure to Pfizer sized 2–3% of portfolio on pullbacks >4% with a 6–12 month horizon to capture pipeline catalysts and steady non-COVID cash flows; hedge COVID sensitivity via relative shorts in Moderna (MRNA) or BioNTech (BNTX). Use options to express asymmetric bets—buy 9–15 month call spreads to limit premium decay around 2–3 expected trial readouts, or buy short-dated puts as tail protection ahead of key announcements.

Contrarian angle: market punished PFE despite an EPS beat—this overreacts to near-term COVID decline while under-discounting durable franchises and 20 planned pivotal studies. If Pfizer delivers 2–4 positive readouts in 2026, upside could re-rate shares by 15–30% as investors refocus on recurring revenue; conversely, dependence on government procurement remains the key fragility and should be monitored weekly (contract notices, CDC guidance).

Key Decisions for Investors

• Establish a 2–3% long position in PFE on any intraday dip >4% from today’s close, target 15–25% total return over 6–12 months conditional on at least one positive late-stage readout or stable guidance; place stop-loss at -12% from entry or if management cuts 2026 mid-point revenue guidance by >5%.
• Implement a relative-value pair: long PFE (2% weight) and short MRNA (1% weight) for 6–12 months to hedge COVID exposure—expect PFE to outperform if non-COVID growth sustains; unwind if Moderna reports a material non-COVID commercial win or PFE guidance is reiterated but COVID sales materially exceed $5B assumption.
• Buy a 9–15 month PFE call spread sized to 1–2% of portfolio premium: long 10% OTM call and short 30% OTM call to capture upside from 1–3 expected 2026 pivotal readouts while capping cost; exit on first positive readout or if IV-adjusted premium decays >50%.
• Reduce or short 1–2% exposure to pure-play COVID/diagnostics small caps and reallocate to large-cap diversified pharma (PFE, RHHBY) over next 30 days; target portfolio shift of 2–4% to reduce pandemic-revenue tail risk and increase defensive cash flow exposure.